| 1 |
Guideline Guidelines for the management of chronic hepatitis C in patients infected after substance use. 2005
Robaeys G, Buntinx F, Bottieau E, Bourgeois S, Brenard R, Colle I, De Bie J, Matheï C, Mulkay JP, Van Damme P, Van Ranst M, Verrando R, Michielsen P, Bourgeois N, Brenard R, de Galocsy Ch, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Reynaert H, Robaeys G, Sprengers D, Anonymous00401. · Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Schiepse Bos, 6, B-3600 Genk, Belgium. · Acta Gastroenterol Belg. · Pubmed #15832586 No free full text.
This publication has no abstract.
|
| 2 |
Review Therapy of chronic hepatitis C in the setting of HIV co-infection. 2005
Michielsen P, Bottieau E. · University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem. · Acta Gastroenterol Belg. · Pubmed #15832592 No free full text.
Abstract: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections are major health problems world-wide. As both viruses partially share routes of transmission, co-infection is common. This is especially the case in patients infected through intravenous drug use. It has been shown that HIV accelerates HCV progression to cirrhosis. The influence of HCV infection on the natural history of HIV disease remains highly controversial. It is also known that HCV co-infection increases the risk of hepatotoxicity of Highly Active Antiretroviral Therapy (HAART). These considerations as well as the improved survival of HIV patients due to HAART leads to increasing numbers of patients undergoing assessment and treatment of HCV infection. HCV treatment should be considered in stable HIV disease. Recent data indicate that HCV treatment schedules should be similar in co-infected and HCV mono-infected individuals, with pegylated interferon combined with ribavirin. For all treatment regimens published, coinfected patients had a lower sustained viral response rate compared to HCV mono-infected patients. Similar predictive factors determine the success rate. The effect of prolonging therapy to 12 months in genotype 2/3 and to 18 months in early viral responders with genotypes 1/4 needs to be assessed in further studies.
|
| 3 |
Article Development of multiple abscesses in an HIV/TB co-infected patient after initiation of antituberculous and highly active antiretroviral therapy. 2002
Bottieau E, Noe A, Florence E, Ostyn B, Colebunders R. · Departement Klinische Wetenschappen, Instituut voor Tropische Geneeskunde, Nationalestraat 155, B-2000 Antwerpen, België. · Acta Clin Belg. · Pubmed #12462798 No free full text.
Abstract: Since the use of Highly Active Antiretroviral Therapy (HAART) for HIV infection, there have been increasing reports of systemic manifestations of immune restoration. This new clinical syndrome among HIV-infected patients is associated with underlying co-infections with mycobacteria, cytomegalovirus, hepatitis B and C infections, etc.... We report on an HIV/tuberculosis (TB) co-infected patient who developed an immune restoration inflammatory syndrome after initiation of HAART and anti-TB treatment. She developed fever, large abscesses and pleural and peritoneal effusions. Systemic symptoms decreased during corticosteroid treatment, but abscesses only disappeared 8 months after the start of the anti-TB treatment.
|
| 4 |
Minor Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. 2004
Callens S, Bottieau E, Michielsen P, Colebunders R. · No affiliation provided · AIDS. · Pubmed #15090841 No free full text.
This publication has no abstract.
|
|
|